Clinical Trials | October 09, 2022
ICON selected by BARDA to conduct anthrax vaccine clinical trial
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
The companies will leverage their respective proprietary technology platforms
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
Therapy recently approved in Canada under the brand name KORSUVA
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
Subscribe To Our Newsletter & Stay Updated
